How often does this podcast release new episodes?

This podcast is currently inactive and not releasing new episodes.

Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

Yes, this podcast regularly features guests.

CAMEO: Lessons Learned about Cangrelor

Claim This Podcast

3 episodes

Updated Inactive

Accepts GuestsHas Sponsors

Podcast Overview

Podcast by CAMEO: Lessons Learned about Cangrelor

Language

🇺🇲

Publishing Since

3/17/2023

Visit Website View on Apple Podcasts RSS Feed

1 verified contact email on file for CAMEO: Lessons Learned about Cangrelor

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

February 14, 2024

Episode 3: A Conversation About Cangrelor and Treating Patients with Cardiogenic Shock

In the third episode of the CAMEO podcast, principal investigator Jennifer Rymer and Babar Basir discuss cangrelor and strategies for treating patients with cardiogenic shock. Tune in to hear their discussion of the pharmacologic considerations for patients with cardiogenic shock and to learn about the National Cardiogenic Shock Initiative at Henry Ford Hospital. You can earn 0.25 CME credits for listening to this episode through the Duke OneLink Continuing Education website. Visit ja.dh.duke.edu/ to create or login to your account and search for CAMEO in the “find a course” field. Follow the steps at duke.is/vy8w8 to register for a Duke One Link account today. Jennifer Rymer, MD, MBA, is the John Bush Simpson Assistant Professor of Medicine at Duke University and Principal Investigator of the CAMEO registry. Dr. Rymer is an interventional cardiologist, and she is a faculty member at the Duke Clinical Research Institute. Dr. Rymer’s disclosures include advisory board and research funding from Chiesi, research funding from Idorsia, and research funding from Pfizer Pharmaceuticals. Babar Basir, DO, is the Director of Acute Mechanical and Circulatory Support at Henry Ford Hospital in Detroit. Dr. Basir’s disclosures include Abiomed, Boston Scientific, Chiesi, Saranas and Zoll. Visit https://duke.is/b/j9ya to view a transcript of this episode.

August 15, 2023

Episode 2: Cangrelor – Upstream P2Y12 Inhibitor Use

In the second episode of the CAMEO podcast, principal investigator Jennifer Rymer and Dominick Angiolillo discuss their recent research examining cangrelor use in the setting of upstream P2Y12 inhibitor use. You can earn 0.25 CME credits for listening to this episode through the Duke One Link Continuing Education website. Visit ja.dh.duke.edu/ to create or login to your account and search for CAMEO in the “find a course” field. Follow the steps at duke.is/vy8w8 to register for a Duke OneLink account today. Jennifer Rymer, MD, MBA, is the John Bush Simpson Assistant Professor of Medicine at Duke University and Principal Investigator of the CAMEO registry. Dr. Rymer is an interventional cardiologist, and she is a faculty member at the Duke Clinical Research Institute. Dr. Rymer’s disclosures include advisory board and research funding from Chiesi, research funding from Idorsia, and research funding from Pfizer Pharmaceuticals. Dominick Angiolillo, MD, PhD, FACC, is Professor and Chief of the Division of Cardiology, Medical Director of the University of Florida Health Cardiovascular Center in Jacksonville, Medical Director of the Cardiovascular Research Program, and Program Director of the Interventional Cardiology Fellowship. Dr. Angiolillo’s disclosures include consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi and Ventura, outside the present work; he has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, Renal Guard Solutions and Scott R. MacKenzie Foundation. Visit https://duke.is/6/rfys to view a transcript of this episode.

March 17, 2023

Episode 1: Observations About P2Y12 Inhibitor Transitions in Cangrelor Treated Patients

In the first episode of the CAMEO podcast, principal investigator Jennifer Rymer and co-investigator Jeff Washam discuss their firsthand experiences with the drug cangrelor and introduce the CAMEO Registry. Tune in to learn more about their recent analysis of CAMEO data, which revealed major variations in clinical use of the drug. You can earn 0.5 CME credits for listening to this episode through the Duke One Link Continuing Education website. Visit https://ja.dh.duke.edu/ to create or login to your account and search for CAMEO in the “find a course” field. Follow the steps at https://duke.is/vy8w8 to register for a Duke OneLink account today. Jennifer Rymer, MD, MBA, is the John Bush Simpson Assistant Professor of Medicine at Duke University and Principal Investigator of the CAMEO registry. Dr. Rymer is an interventional cardiologist, and she is a faculty member at the Duke Clinical Research Institute. Jeffrey Washam, PharmD, FAHA, is a clinical pharmacist in the Cardiac Intensive Care Unit at Duke University Hospital, co-investigator of the CAMEO registry, and a consulting associate in the Duke Department of Medicine. Visit https://duke.is/rwd3w to view a transcript of this episode.

3 total episodes available

Deep-dive analytics for CAMEO: Lessons Learned about Cangrelor

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is CAMEO: Lessons Learned about Cangrelor?: Podcast by CAMEO: Lessons Learned about Cangrelor
How often does this podcast release new episodes?: This podcast updates inactive.
Where can I listen to this podcast?: This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: Yes, this podcast regularly features guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.